Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Genmab

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Employees: 2.2K

Market Cap: $17.7B

Website: http://www.genmab.com

Clinical Trials

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: zalutumumab

First Posted Date: 2011-10-10

Last Posted Date: 2011-10-10

Lead Sponsor: Genmab

Registration Number: NCT01449357

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: zalutumumab

First Posted Date: 2010-01-22

Last Posted Date: 2023-08-03

Lead Sponsor: Genmab

Target Recruit Count: 31

Registration Number: NCT01054625

Locations: 🇧🇪
Cliniques Universitaires SaintLuc, Brussels, Belgium
🇧🇪
Uz Leuven - Campus Gasthuisberg, Leuven, Belgium
🇭🇺
Uzsoki Hospital, Budapest, Hungary

and more 4 locations

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: Zalutumumab

First Posted Date: 2008-07-01

Last Posted Date: 2023-08-03

Lead Sponsor: Genmab

Target Recruit Count: 8

Registration Number: NCT00707655

Locations: 🇧🇪
St-Luc University Hospital, Brussels, Belgium
🇫🇷
Centre Georges-Francois Leclerc Hospital, Dijon, France
🇫🇷
Medical Oncology, Outpatient Clinic, Nantes, France

and more 5 locations

Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Zalutumumab

First Posted Date: 2008-05-15

Last Posted Date: 2023-07-18

Lead Sponsor: Genmab

Target Recruit Count: 9

Registration Number: NCT00677924

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Hospital Erasme, Brussels, Belgium
🇧🇪
St-Luc University Hospital, Brussels, Belgium

Zalutumumab in Non-curable Patients With SCCHN

Phase 2

Completed

Conditions: Head and Neck Cancer
Squamous Cell Cancer

Interventions: Drug: Zalutumumab

First Posted Date: 2007-10-11

Last Posted Date: 2023-08-03

Lead Sponsor: Genmab

Target Recruit Count: 90

Registration Number: NCT00542308

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Loma Linda University Cancer Institute, Loma Linda, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 45 locations

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Zalutumumab
Drug: Induction chemotherapy
Radiation: Radiotherapy

First Posted Date: 2007-04-16

Last Posted Date: 2011-12-06

Lead Sponsor: Genmab

Target Recruit Count: 13

Registration Number: NCT00460551

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇧🇪
UZ Gent, Gent, Belgium
🇧🇪
CHR La Citadelle, Liege, Belgium

and more 4 locations

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Phase 1

Terminated

Conditions: Squamous Cell Cancer
Head and Neck Cancer

Interventions: Drug: zalutumumab
Drug: cisplatin
Procedure: Radiotherapy

First Posted Date: 2006-11-20

Last Posted Date: 2011-12-23

Lead Sponsor: Genmab

Target Recruit Count: 30

Registration Number: NCT00401401

Locations: 🇺🇸
Oregon Health Sciences Center, Portland, Oregon, United States
🇧🇪
St-Luc University Hospital, Brussels, Belgium
🇧🇪
University Hospital Gasthuisberg, Leuven, Belgium

and more 4 locations

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Phase 3

Completed

Conditions: Head and Neck Cancer
Squamous Cell Cancer

Interventions: Drug: Zalutumumab
Other: Control

First Posted Date: 2006-09-28

Last Posted Date: 2013-10-15

Lead Sponsor: Genmab

Target Recruit Count: 286

Registration Number: NCT00382031

Locations: 🇧🇪
University Hospital Antwerp, Antwerp, Belgium
🇧🇪
St-Luc University Hospital, Brussels, Belgium
🇧🇪
CHNDRF, Charleroi, Belgium

and more 79 locations

Zalutumumab in Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Zalutumumab

First Posted Date: 2004-10-01

Last Posted Date: 2023-06-28

Lead Sponsor: Genmab

Target Recruit Count: 28

Registration Number: NCT00093041

Locations: 🇩🇰
Rigshospitalet, Copenhagen Ø, Denmark
🇩🇰
Odense Universitetshospital, Odense, Denmark
🇩🇰
Århus Kommunehospital, Århus C, Denmark

and more 2 locations

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Phase 2

Completed

Conditions: Cutaneous T-Cell Lymphoma

Interventions: Drug: HuMax-CD4

First Posted Date: 2003-10-15

Last Posted Date: 2023-05-18

Lead Sponsor: Genmab

Target Recruit Count: 25

Registration Number: NCT00071071

Locations: 🇺🇸
Stanford University Med. Ctr., Dept. of Dermatology, Stanford, California, United States
🇺🇸
University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy